Cephalon has completed its acquisition of all the outstanding ordinary shares of the Australian biotech firm Arana Therapeutics. It acquired a controlling stake in the company in May.
The acquisition marks Cephalon's entry into the biologics business. Arana, now a wholly owned subsidiary of Cephalon, has a domain...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?